In 2023, the use of antiarrhythmic medicine in South Korea stood at 2.4 Defined Daily Dosage (DDD) per thousand persons per day. From 2024 onwards, forecasted data indicates a consistent annual increase in usage, escalating from 2.6 DDD in 2024 to 3.4 DDD by 2028. This signifies a steady year-on-year growth of approximately 7.7% from 2024 to 2025, 7.1% from 2025 to 2026, 6.7% from 2026 to 2027, and 6.3% from 2027 to 2028. The Compound Annual Growth Rate (CAGR) over this five-year forecast period is an impressive 7.0%.
Future trends to watch for include potential advancements in antiarrhythmic drug formulations, increased prevalence of heart-related ailments due to aging populations, improvements in healthcare access, and broader adoption of personalized medicine. Staying attuned to these factors could provide valuable insights into market dynamics and future demand for antiarrhythmic medications in South Korea.